Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News THT 2023

High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF

Todd Neale

March 23, 2023

News Conference News THT 2023

Meta-analysis Hints at Survival Benefit With LAP Monitoring in HFrEF

Shelley Wood

March 22, 2023

News Conference News THT 2023

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

Yael L. Maxwell

March 22, 2023

News Conference News THT 2023

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

Todd Neale

March 22, 2023

News Conference News THT 2023

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

Todd Neale

March 21, 2023

News Conference News THT 2023

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

Caitlin E. Cox

March 21, 2023

$Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?$

Presentation THT 2023

Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?

Presenter: Michael Sutherland

March 21, 2023

Presentation THT 2023

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

Presenter: Margaret Cuomo

March 21, 2023

News Conference News THT 2023

TEER or VAD/Transplant in the Advanced HF Patient With MR?

Shelley Wood

March 20, 2023

News Conference News THT 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

Todd Neale

March 20, 2023

Presentation THT 2023

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Presenter: William Abraham

March 20, 2023

Advertisement

High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF

Meta-analysis Hints at Survival Benefit With LAP Monitoring in HFrEF

REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests

Preliminary Results Suggest Benefit of Splanchnic Nerve Ablation in HFpEF

Promising Preliminary Results for AccuCinch LV Restoration System in HFrEF

Higher Gradient After Tricuspid TEER Not Harmful at 1 Year: TriValve Registry

Hierarchical composite endpoints for heart failure trials - answering the question: What fraction of the composite endpoint is due to cardiovascular mortality, hospitalization, or quality of life?

Cardiovascular Hospitalization Rates in ATTR-CA: What Factors Make a Difference

TEER or VAD/Transplant in the Advanced HF Patient With MR?

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

What are the Strengths and Limitations of a Two-Phase (6-Month Intermediate Endpoints & 12-18 Month Mortality and Heart Failure Hospitalization) Trial Design

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content